Purple Biotech (PPBT) Total Liabilities (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Total Liabilities data on file, last reported at $4.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $4.7 million, up 59.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 million (up 59.37% YoY), and the FY2025 annual result was $7.9 million, up 90.4% from the prior year.
• Total Liabilities eased to $4.7 million in Q1 2026 per PPBT's latest filing, from $7.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $10.0 million in Q4 2023 and troughed at $2.4 million in Q2 2025.
• A 5-year average of $6.3 million and a median of $6.3 million in 2022 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 90.4% in 2025 and fell as far as 66.69% in 2025.
• A 5-year view of Total Liabilities shows it stood at $7.5 million in 2022, then jumped by 32.97% to $10.0 million in 2023, then tumbled by 58.75% to $4.1 million in 2024, then jumped by 90.4% to $7.9 million in 2025, then slumped by 40.25% to $4.7 million in 2026.
• Business Quant data shows PPBT's Total Liabilities at $4.7 million in Q1 2026, $7.9 million in Q4 2025, and $6.3 million in Q3 2025.